Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by forrest6748on Oct 25, 2021 9:32pm
217 Views
Post# 34047987

Biden to speed authorization of at-home Covid tests

Biden to speed authorization of at-home Covid tests
Biden administration announces plan to speed authorization of at-home Covid tests
Government health experts will work with test-makers and guide them through a streamlined FDA process as part of a new $70 million program.


https://www.nbcnews.com/politics/white-house/biden-administration-announces-plan-accelerate-authorization-home-covid-tests-n1282255

The Biden administration on Monday announced several steps aimed at making rapid, at-home Covid testing more widely available while lowering costs.

The U.S. Food and Drug Administration is streamlining its authorization process, while the National Institutes of Health will spend $70 million on a new program to accelerate test-makers through those regulatory hurdles. The funds will come from the American Rescue Plan, the $1.9 trillion Covid relief package President Joe Biden signed into law in March.

 

The announcement comes as businesses prepare to implement Biden’s vaccinate-or-test mandate. The administration has for months faced criticism that at-home rapid tests are not widely available and that those on the market are too expensive.

The FDA also said Monday it has issued emergency use authorization to another over-the-counter rapid antigen test by the company Celltrion Diatrust, bringing the total number of rapid, at-home tests available to the public to 10.


<< Previous
Bullboard Posts
Next >>